Literature DB >> 9173039

[Torsade de pointes tachycardia during administration of quinidine and verapamil in atrial fibrillation].

M Karch1, C Schmitt, A Plewan, G Schmidt, A Schömig.   

Abstract

The following case report shows that life threatening arrhythmias with fatal consequences may occur after treatment with Cordichin a combination of 80 mg verapamil and 160 mg quinidine. A 65-year-old woman was treated with Cordichin due to atrial fibrillation lasting for 3 months. After the first day of treatment the patient suddenly collapsed with loss of consciousness. The patient was resuscitated 15 min later. The emergency physician diagnosed a cardiac arrest. After cardiopulmonary resuscitation and intubation stable circulation was restored. When the patient was admitted in our hospital the ECG showed numerous ventricular extrasystoles, marked prolongation of the QT interval (700 ms) (Figures 1a and b) and nonsustained polymorphic ventricular tachycardias (Figure 2). The arrhythmias could be suppressed by right ventricular stimulation after inserting a pacemaker lead. After a period of 12 h a normal QT interval was restored (Figure 3). Unfortunately the patient died 3 days later due to irreversible cerebral damage. The concept of suppressing proarrhythmic effects of quinidine by calcium antagonists is discussed. Despite theoretical advantages of a combination therapy this case report shows that life threatening dysrhythmias cannot be prevented by additional calcium antagonism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9173039     DOI: 10.1007/BF03044570

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  24 in total

1.  QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

Authors:  A SELZER; H W WRAY
Journal:  Circulation       Date:  1964-07       Impact factor: 29.690

Review 2.  Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?

Authors:  B Surawicz
Journal:  J Am Coll Cardiol       Date:  1989-07       Impact factor: 24.094

3.  Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes.

Authors:  J J Salata; J A Wasserstrom
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

4.  [Ventricular tachycardia with 2 variable opposing foci].

Authors:  F Dessertenne
Journal:  Arch Mal Coeur Vaiss       Date:  1966-02

Review 5.  Clinical safety profile of sotalol in patients with arrhythmias.

Authors:  L F Soyka; C Wirtz; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

6.  Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest.

Authors:  J N Ruskin; B McGovern; H Garan; J P DiMarco; E Kelly
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

7.  Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans.

Authors:  K Nademanee; W G Stevenson; J N Weiss; V B Frame; M G Antimisiaris; T Suithichaiyakul; C M Pruitt
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

8.  Sotalol intoxication, two patients with concentration-effect relationships.

Authors:  P J Neuvonen; E Elonen; L Tarssanen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-07

9.  Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms.

Authors:  S Nattel; M A Quantz
Journal:  Cardiovasc Res       Date:  1988-11       Impact factor: 10.787

10.  QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Afterdepolarizations and ventricular arrhythmias.

Authors:  N el-Sherif; R H Zeiler; W Craelius; W B Gough; R Henkin
Journal:  Circ Res       Date:  1988-08       Impact factor: 17.367

View more
  1 in total

Review 1.  Risk factors for drug-induced long-QT syndrome.

Authors:  A D C Paulussen; J Aerssens
Journal:  Neth Heart J       Date:  2005-02       Impact factor: 2.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.